Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Payables (2019 - 2025)

Historic Payables for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $6.9 million.

  • 4D Molecular Therapeutics' Payables rose 13471.27% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 13471.27%. This contributed to the annual value of $4.4 million for FY2024, which is 2477.95% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Payables stood at $6.9 million for Q3 2025, which was up 13471.27% from $8.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Payables high stood at $8.7 million for Q2 2025, and its period low was $1.3 million during Q1 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Payables averaged around $3.8 million, with its median value being $3.5 million (2023).
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Payables crashed by 6014.0% in 2022, and later skyrocketed by 21844.59% in 2023.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Payables stood at $4.8 million in 2021, then plummeted by 30.27% to $3.3 million in 2022, then grew by 5.81% to $3.5 million in 2023, then grew by 24.78% to $4.4 million in 2024, then surged by 56.48% to $6.9 million in 2025.
  • Its Payables stands at $6.9 million for Q3 2025, versus $8.7 million for Q2 2025 and $4.2 million for Q1 2025.